Coordination compounds of Cu(ii), Ni(ii), Co(ii), and Zn(ii) with a type of biguanide were obtained and structurally characterized. The new metal-drugs present biological applications as potential drugs for diabetes and metabolic syndrome.

Osteoarthritis (OA) pain has been proposed to be a mixed pain state, because in some patients, central nervous system factors are superimposed upon the more traditional peripheral factors. In addition, a considerable amount of preclinical and clinical evidence has shown that, accompanying the central neuroplasticity changes and partially driven by a peripheral nociceptive input, a real neuropathic component occurs that are particularly linked to disease severity and progression. Hence, innovative strategies targeting neuroprotection and particularly neuroinflammation to prevent and treat OA pain could be introduced. Mangiferin (MG) is a glucosylxanthone that is broadly distributed in higher plants, such as Mangifera indica L. Previous studies have documented its analgesic, anti‐inflammatory, antioxidant, neuroprotective, and immunomodulatory properties. In this paper, we propose its potential utility as a multitargeted compound for mixed OA pain, even in the context of multimodal pharmacotherapy. This hypothesis is supported by three main aspects: the cumulus of preclinical evidence around this xanthone, some preliminary clinical results using formulations containing MG in clinical musculoskeletal or neuropathic pain, and by speculations regarding its possible mechanism of action according to recent advances in OA pain knowledge.

No abstract

Context: Several experimental results and clinical reports using Mangifera indica L extract (MSBE) suggest its potential utility in osteoarthritis (OA) mixed pain. Aims: To examine the possible therapeutic effects and safety of supplementation on osteoarthritis (OA) pain. Methods: Fifty patients with painful knee OA who had undergone a year of conventional treatment that included paracetamol and non-pharmacological therapies were randomly allocated to the experimental group (n = 21), which received a daily dose of 900 mg of extract supplementation or preceding usual treatment and placebo in the same form (n = 17) for a period of 120 days. The primary measure outcome was the change in the average daily pain diary score (ADPS) using the Likert scale. Also, a multidimensional measure of pain, stiffness and functional disability on The Western Ontario and Mc Master Universities (WOMAC) index for knee OA and ultrasonographic chronic signs of synovitis such as effusion and synovial thickness were evaluated. Results: Change from baseline in ADPS of the MSBE supplemented group showed a significant reduction after two weeks that lasted for 120 days with respect to the placebo group. Significant improvements in pain and functional disability WOMAC sub-scores, number of joints with synovial thickness and effusion after MSBE supplementation vs. placebo were observed. Non-adverse effects were reported in the experimental group. Conclusions: These results suggest that MSBE supplementation has a beneficial effect on OA pain and disability.

The transition metals, specifically biometals such as Co, Cu, Zn and Ni, are being the target of numerous scientific studies from different branches of chemistry, medicine and pharmacology. These metals are well known to form bonds and interactions with biomolecules. Also, are often responsible for the biological function of biomolecules in the body, are immersed in many biochemical processes essential for life. In addition, these metal cations have a great tendency to form coordination compounds with numerous types of ligands. Into the medical-pharmacological field is the medicinal inorganic chemistry that explores binding agents with therapeutic properties linked to metal cations and their multiple applications. 1,2 this work focuses on the synthesis, characterization and structural study of complexes based on metformin and transition metals as Co(II), Cu(II), Ni(II) and Zn(II), in order to propose new therapeutic alternatives, by taking advantage of the characteristics of current drugs in synergy with the activity of metallic cations. 3